Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas

Histopathology

Volumn 36, Issue 2, 2000, Pages 168-177

  Gobbi, H ^a,c   Arteaga, C L ^a,b   Jensen, R A ^a   Simpson, J F ^a   Dupont, W D ^a   Olson, S J ^a   Schuyler, P A ^a   Plummer, W D ^a   Page, D L ^a  

^a Department of Pathology ^*  (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Benign breast disease; Ductal carcinoma in situ; Immunohistochemistry; Invasive mammary carcinoma; Transforming growth factor receptors

Indexed keywords

ESTROGEN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CARCINOMA IN SITU; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 0034004714     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00841.x     Document Type: Article

References (84)

1. 1. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4; 193-201.
2. 2. Arteaga CL, Dugger TC, Hurd SD. The multifunctional role of transforming growth factor (TGF)-betas on mammary epithelial cell biology. Breast Cancer Res. Treat 1996; 38; 49-56.
3. 3. Brattain MG, Ko Y, Banerji SS, Wu G, Willson JKV. Defects of TGF-beta receptor signaling in mammary cell tumorigenesis. J. Mamm. Gland Biol. Neoplasia 1996; 1; 365-372.
4. 4. Koli KM, Arteaga CL. Transforming growth factor-betas and breast carcinoma. In: Bowcock AM, ed. Breast Cancer. Totowa, NJ: Humana Press, 1998.
5. 5. Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massague J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 1990; 265; 20533-20538.
6. 6. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370; 341-347.
7. 7. Massague J. TGF-beta signaling: receptors, transducers, and Mad proteins. Cell 1996; 85; 947-950.
8. 8. Koli KM, Arteaga CL. Processing of the transforming growth factor beta type I and II receptors. Biosynthesis and ligand-induced regulation. J. Biol. Chem. 1997; 272; 6423-6427.
9. 9. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 1993; 92; 2569-2576.
10. 10. Dickson RB, Bates SE, McManaway ME, Lippman ME. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res. 1986; 46; 1707-1713.
11. 11. Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M, Sager R. Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res. 1988; 48; 7041-7047.
12. 12. Lyons RM, Miller DA, Graycar JL, Moses HL, Derynck R. Differential binding of transforming growth factor-beta 1-beta 2, and -beta 3 by fibroblasts and epithelial cells measured by affinity cross-linking of cell surface receptors. Mol. Endocrinol 1991; 5; 1887-1896.
13. 13. McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB. Localization of transforming growth factor-beta isotypes in lesions of the human breast. Hum. Pathol. 1992; 23; 13-20.
14. 14. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. 1993; 143; 381-389.
15. 15. Dublin EA, Barnes DM, Wang DY, King RJ, Levison DA. TGF alpha and TGF beta expression in mammary carcinoma. J. Pathol. 1993; 170; 15-22.
16. 16. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes RC. The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer 1993; 67; 1408-1412.
17. 17. Walker RA, Dearing SJ, Gallacher B. Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br. J. Cancer 1994; 69; 1160-1165.
18. 18. Auvinen P, Lipponen P, Johansson R, Syrjanen K. Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer. Anticancer Res. 1995; 15; 2627-2631.
19. 19. Baillie R, Coombes RC, Smith J. Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1. Eur J. Cancer 1996; 32A; 1566-1573.
20. 20. Pilichowska M, Kimura N, Fujiwara H, Nagura H. Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma. Mod. Pathol. 1997; 10; 969-975.
21. 21. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I. An inventory in search of autocrine and paracrine loops. J. Pathol. 1998; 184; 44-52.
22. 22. Mizukami Y, Nonomura A, Yamada T et al. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res. 1990; 10; 1115-1126.
23. 23. Barrett-Lee P, Travers M, Luqmani Y, Coombes RC. Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br. J. Cancer 1990; 61; 612-617.
24. 24. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992; 52; 6949-6952.
25. 25. Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J. Cancer 1992; 28; 641-644.
26. 26. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268; 1336-1338.
27. 27. Kim IY, Ahn H-J, Zelner DJ et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 1996; 2; 1255-1261.
28. 28. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 1997; 57; 5564-5570.
29. 29. Izumoto S, Arita N, Ohnishi T et al. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett. 1997; 112; 251-256.
30. 30. Lazzereschi D, Ranieri A, Mincione G, Taccogna S, Nardi F, Colletta G. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res. 1997; 57; 2071-2076.
31. 31. Gerdes MJ, Larsen M, McBride L, Dang TD, Lu B, Rowley DR. Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues. J. Histochem. Cytochem. 1998; 46; 379-388.
32. 32. Lynch MA, Nakashima R, Song H et al. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res. 1998; 58; 4227-4232.
33. 33. MacKay SL, Auffenberg T, Tannahill CL et al. Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype. Ann. Surg. 1998; 227; 781-789.
34. 34. Sun L, Wu G, Willson JK et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol Chem. 1994; 269; 26449-26455.
35. 35. Brattain MG, Markowitz SD, Willson JK. The type II transforming growth factor-beta receptor as a tumor-suppressor gene. Curr. Opin. Oncol. 1996; 8; 49-53.
36. 36. Ko Y, Banerji SS, Liu Y et al. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J. Cell Physiol. 1998; 176; 424-434.
37. 37. Ko Y, Koli KM, Banerji SS et al. A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells. Int. J. Oncol. 1998; 12; 87-94.
38. 38. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis. J. Pathol. 1998; 184; 53-57.
39. 39. Younes M, Fernandez L, Laucinca R. Transforming growth factor-beta receptor II (TGF-beta-RII) is infrequently expressed in human breast cancer. Breast J. 1996; 2; 150-153.
40. 40. Page DL, Anderson TJ, Rogers LW. Epithelial hyperplasia. In: Page DL Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987: 120-156.
41. 41. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum. Pathol. 1991; 22; 1232-1239.
42. 42. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol. 1992; 23; 1095-1097.
43. 43. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum. Pathol 1997; 28; 967-973.
44. 44. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL Anderson RJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987: 300-311.
45. 45. Elston CW, Ellis IO. Assessment of histological grade. In: Elston CW Ellis IO. eds. The Breast, Vol. 13. Edinburgh: Churchill Livingstone, 1998: 365-384.
46. 46. Gold LI, Sung JJ, Siebert JW, Longaker MT. Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair. Am. J. Pathol. 1997; 150; 209-222.
47. 47. de Boer WI, Schuller AG, Vermey M, van der Kwast TH. Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo. Am. J. Pathol. 1994; 145; 1199-1207.
48. 48. Roy SK, Kole AR. Transforming growth factor-beta receptor type II expression in the hamster ovary: cellular site(s), biochemical properties, and hormonal regulation. Endocrinology 1995; 136; 4610-4620.
49. 49. Battifora H, Mehta P, Ahn C, Esteban JM. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. Appl. Immunohistochem. 1993; 1; 39-45.
50. 50. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
51. 51. Breslow NE, Day NE. Statistical methods in cancer research. The Analysis of Case-Control. Studies, Vol. 1. Lyon, France: IARC Scientific Publications, 1980.
52. 52. SAS Institute Inc. SAS/STAT User's Guide, Version 6, Vol. 1, 4th edn. Cary NC: SAS Institute, Inc., 1989.
53. 53. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes C. Localization of basic fibroblastic growth factor and transforming growth factor beta1 in the human mammary gland. Cancer Res. 1991; 51; 4685-4692.
54. 54. Gobbi H, Dupont WD, Arteaga CL et al. Loss of transforming growth factor beta receptor II expression in epithelial hyperplasia without atypia increases the subsequent breast cancer risk. Mod Pathol 1999; 12; 21A.
55. 55. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl. J. Med. 1985; 312; 146-151.
56. 56. Dupont WD, Parl FF, Hartmann WH et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71; 1258-1265.
57. 57. Fitzgibbons PL, Henson DE, Hutter RVP, Canc Comm Coll Am. P. Benign breast changes and the risk for subsequent breast cancer - an update of the 1985 consensus statement. Arch. Pathol. Lab. Med. 1998; 122; 1053-1055.
58. 58. Page DL, Dupont WD. Benign breast diseases and premalignant breast disease. Arch. Pathol. Lab. Med. 1998; 122; 1048-1050.
59. 59. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J. Natl. Cancer Inst. 1998; 90; 1262-1269.
60. 60. Millikan R, Hulka B, Thor A et al. p53 mutations in benign breast tissue. J. Clin. Oncol. 1995; 13; 2293-2300.
61. 61. O'Malley FP, Page DL, Nelson EH, Dupont WD. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum. Pathol. 1994; 25; 164-168.
62. 62. Page DL, Simpson JF. Pathology of preinvasive and excellent-prognosis breast cancer. Curr. Opin. Oncol. 1996; 8; 462-467.
63. 63. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum. Pathol 1998; 29; 1539-1545.
64. 64. Page DL, Jensen RA, Simpson JE. Premalignant and malignant disease of the breast: the roles of the pathologist. Mod. Pathol. 1998; 11; 120-128.
65. 65. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab. Invest. 1994; 71; 67-72.
66. 66. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 1995; 75; 2123-2131.
67. 67. Schmitt FC. Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur. J. Cancer 1995; 31A; 2049-2052.
68. 68. Weinstat-Saslow D, Merino MJ, Manrow RE et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1995; 1; 1257-1260.
69. 69. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am. J. Pathol. 1997; 151; 161-168.
70. 70. Lawrence JA, Merino MJ, Simpson JF, Manrow RE, Page DL, Steeg PS. A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor. Cancer Epidemiol. Biomarkers Prev. 1998; 7; 29-35.
71. 71. Quinn CM, Ostrowski JL, Harkins L, Rice AJ, Loney DP. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins. Histopathology 1998; 33; 531-536.
72. 72. Kim IY, Ahn HJ, Lang S et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res. 1998; 4; 1625-1630.
73. 73. Sue SR, Chari RS, Kong FM et al. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann. Surg. 1995; 222; 171-178.
74. 74. Garrigue-Antar L, Souza RF, Velluci VF, Meltzer SJ, Reiss M. Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab. Invest. 1996; 75; 263-272.
75. 75. Abe T, Ouyang H, Migita T et al. The somatic mutation frequency of the transforming growth factor beta receptor type II gene varies widely among different cancers with microsatellite instability. Eur J. Surg. Oncol. 1996; 22; 474-477.
76. 76. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996; 10; 2462-2477.
77. 77. Oft M, Heider K-H, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 1998; 8; 1243-1252.
78. 78. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am. J. Clin. Pathol. 1995; 104; 42-49.
79. 79. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991; 68; 1309-1317.
80. 80. van Diest PJ, Baak JP, Matze-Cok P et al. Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum. Pathol 1992; 23; 603-607.
81. 81. Page DL. Prognostic indicators in breast cancer and who needs them. Anat. Pathol. 1997; 2; 35-52.
82. 82. Pinder SE, Murray S, Ellis IO et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 1998; 83; 1529-1539.
83. 83. Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M. Transforming growth factor beta and cancer. Cancer Treat. Rev. 1995; 21; 367-403.
84. 84. Sun P, Dong P, Dai K, Hannon GJ, Beach D. p53-independent role of MDM2 in TGF-beta1 resistance. Science 1998; 282; 2270-2272.